EOLS Evolus, Inc. logo

EOLS Evolus, Inc.

Healthcare
$6.09-5.58%ClosedMarket Cap: $401.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

-13.79

P/S

1.33

EV/EBITDA

-36.78

DCF Value

$8.26

FCF Yield

-10.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

65.5%

Operating Margin

-9.6%

Net Margin

-14.4%

ROE

174.9%

ROA

-19.7%

ROIC

-18.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$73.1M$-10.7M$
Q4 null$90.3M$130.0K$
FY null$297.2M$-51.6M$
Q3 null$69.0M$-15.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$15.00

Target (Median)

$15.00

Target Range

$13.00 - $17.00

1 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
BTIGBuy
2026-03-04
HC Wainwright & Co.Buy
2026-02-03
BTIGBuy
2026-01-22
StifelBuy
2026-01-13
NeedhamHold
2025-12-24

Trading Activity

Insider Trades

View All
MOATAZEDI DAVIDdirector, officer: See Remarks
SellFri Mar 20
Avelar Ruiofficer: See Remarks
SellFri Mar 20
MOATAZEDI DAVIDdirector, officer: See Remarks
SellWed Mar 18
MOATAZEDI DAVIDdirector, officer: See Remarks
SellWed Mar 18
Avelar Ruiofficer: See Remarks
SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

1.29

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Peers